Additional events in the RE-LY trial

New England Journal of Medicine

Volumn 371, Issue 15, 2014, Pages 1464-1465

  Connolly, Stuart J ^a   Wallentin, Lars ^b   Yusuf, Salim ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UPPSALA CLINICAL RESEARCH CENTER   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; DABIGATRAN; WARFARIN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; DRUG DERIVATIVE;

ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; DEATH; DRUG EFFECT; EMBOLISM; FATALITY; HOSPITALIZATION; HUMAN; INJURY; LETTER; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMIC DISEASE; CEREBROVASCULAR ACCIDENT; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; MORTALITY;

BENZIMIDAZOLES; BETA-ALANINE; HEMORRHAGE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; WARFARIN;

EID: 84907863384     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1407908     Document Type: Letter

References (3)

1. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139-51.
2. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med 2010;363:1877.
3. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Newly identified events in the RE-LY trial. N Engl J Med 2010; 363:1875-6.